[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombocytopaenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombocytopaenia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100571617","phase-4-sirolimus-monotherapy-in-the-treatment-of-antiphospholipid-antibody-related-thrombocytopenia-100571617",false,"NCT06722586","Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia","Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia: a Multicenter Randomized, Double Blind, Placebo Controlled, Clinical Trial","SMART","Inclusion Criteria:\n\n* persistent positive of antiphospholipid antibody (either lupus anticoagulant, anti-cardiolipin antibody, or anti-b2GP1 antibody, at least two times with 12 weeks apart)\n* persistent thrombocytopenia (30-100×10\\^9\u002FL, at least for 2 weeks)\n\nEligible concomitant treatment:\n\n* prednisone or equivalent dose less than 10mg per day is allowed, and dose should be stable for more than 2 weeks\n* hydroxychloroquine less than 400mg per day is allowed, and dose should be stable for more than 1 month\n* anti-platelet and\u002For anti-coagulant therapy is allowed, and strength should be the stable for 1 week\n* these following therapies should be discontinued for more than 5 half-lives before the enrollment, including thrombopoietin or thrombopoietin receptor antagonist, intravenous immunoglobulin, immunosuppressants, B cell inhibitors (Belimumab or Talitacicept) and B cell depletion therapy (Rituximab or Obinutuzumab).\n\nExclusion Criteria:\n\n* fulling the criteria of other connective tissue disease other than antiphospholipid syndrome\n* received oral\u002Fintravenous antibiotics within 2 weeks before the enrollment.\n* new onset of thrombosis within 4 weeks before the enrollment.\n* apparent bleeding tendency.\n* life or organ threatening manifestations, includes but not limit to catastrophic antiphospholipid syndrome and thrombotic microangiopathy.\n* liver and renal dysfunction: ALT or AST more than three times of upper limit of normal range; eGFR\\\u003C40mL\u002Fmin\u002F1.73m\\^2\n* hematocytopenia: WBC\\\u003C3.0×10\\^9\u002FL, Hb\\\u003C100g\u002FL.\n* uncontrollable hyperlipidemia: low density lipoprotein cholesterol\\>3.1 mmol\u002FL, triglycerides\\>2.3 mmol\u002FL after lipid lowering therapy.\n* current active infection\n* women in pregnancy and postpartum period","ALL","18 Years",{"count":20,"type":21},84,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of sirolimus in patients with anti-phospholipid antibody-associated thrombocytopenia.\n\nIn the 6-month randomized, double-blind, placebo-controlled phase, participants will receive either sirolimus 1 mg once daily or matching placebo. Participants will be followed at 2 weeks, 1 month, 3 months, and 6 months after enrollment.\n\nParticipants who do not achieve the primary endpoint at 6 months may enter a 3-month open-label extension and receive sirolimus 1.5 mg once daily, with follow-up through month 9.\n\nThe main question is whether sirolimus improves the overall response rate at 6 months compared with placebo.\n\nPrimary outcome:\n\n\\- Overall response rate at 6 months\n\nSecondary outcomes:\n\n* Overall response rate at 1 month and 3 months\n* Complete response rate at 6 months\n* Partial response rate at 6 months\n* Change in anti-phospholipid antibody titers at 6 months\n* Change in oral glucocorticoid dosage at 6 months\n\nExploratory outcomes:\n\n* Proportion and reasons for early discontinuation during the double-blind phase\n* Among participants who do not achieve the primary endpoint at 6 months and enter the open-label extension, overall response rate, complete response rate, partial response rate, and safety outcomes after 3 months of open-label treatment",[27,28],"Antiphospholipid (aPL)-Positive","Thrombocytopaenia",[30,31,32,33,34],"antiphospholipid","thrombocytopaenia","sirolimus","rapamycin","mTOR inhibitor","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2025-01-07",{"date":43,"type":21},"2027-12",{"name":45,"class":46},"Peking University First Hospital","OTHER",10,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100614366","phase-2-preoperative-use-of-romiplostim-in-thrombocytopenic-patients-undergoing-cardiac-surgery-100614366","NCT07278661","Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.","Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. A Phase 3, Multicenter Randomized Double-blinded Controlled Against Placebo Study.","CT-PLATE","Inclusion Criteria:\n\n* Adult patients with no upper age limit,\n* Scheduled cardiac surgery with cardiopulmonary bypass,\n* Patients with preoperative thrombocytopenia strictly \\\u003C150,000\u002Fmm3\n* Surgery performed with a blood recovery system using centrifugation (Cell Saver type) or equivalent,\n* Feasibility of a first injection (Romiplostim or Placebo) between D-14 and D-10 before surgery,\n* Surgery requiring the administration of antiplatelet and\u002For anticoagulant therapy for a minimum of 1 month postoperatively.\n\nExclusion Criteria:\n\n* Inability to administer the first injection of Romiplostim or Placebo within 10 days prior to surgery,\n* Cardiac surgery without cardiopulmonary bypass,\n* Coronary artery bypass grafting due to one or more significant coronary stenoses,\n* Tangential filtration blood recovery system (i-SEP SAME® type) planned for intraoperative use or absence of intraoperative blood recovery system due to investigator choice or availability issues,\n* Planned use of aprotinin as an antifibrinolytic agent during surgery,\n* Patient with contraindication to discontinuation of all antiplatelet therapy before surgery (with discontinuation at least 3 days before surgery for acetylsalicylic acid and at least 5 days before surgery for clopidogrel\u002Fticagrelor),\n* Hereditary or acquired thrombophilia with or without a history of thrombosis,\n* History of ischemic or hemorrhagic stroke,\n* History of phlebitis, pulmonary embolism, or portal vein thrombosis,\n* History of heart attack with stent placement less than one year ago,\n* Current limb immobilization (e.g., plaster cast for ankle fracture) or inability to walk independently due to limited mobility (e.g., paralysis),\n* Current immobilization of a limb (e.g., plaster cast for ankle fracture) or inability to walk independently due to motor limitation (e.g., complete paralysis of a limb) or medical contraindication (e.g., strict bed rest required),\n* Myelogram indicating malignant hematological disease or blast cells strictly greater than 5%,\n* Malignant diseases with last follow-up indicating disease progression,\n* Severe chronic liver disease with a CHILD-PUGH score \\> 6 (measured without decompensation),\n* Treatment with thrombopoietin receptor agonist received within 3 months prior to inclusion,\n* Treatment with JAK2 inhibitor currently underway or within the last month,\n* Treatment with Rituximab within the last 7.5 months or intravenous immunoglobulin within the last 40 days,\n* Ongoing treatment with corticosteroids at doses equal to or greater than 20mg of hydrocortisone, 5mg of prednisone\u002For prednisolone, 4mg of methylprednisone, or 0.75mg of dexamethasone,\n* Known hemophilia,\n* Hypersensitivity to romiplostim or any of its excipients, or to proteins derived from E. coli,\n* Context of hyperchloremia, hypernatremia, or major water and salt retention with anasarca refractory to medical treatment,\n* Pregnant women or women of childbearing age who are not using effective contraception,\n* Currently using combined oral contraceptive pills or oral hormone replacement therapy containing estrogen,\n* Breastfeeding women,\n* Minors,\n* Adults under guardianship, curatorship, or judicial protection,\n* Patients who do not speak French,\n* Patients without Social Security coverage.",{"count":57,"type":21},136,[59],"PHASE2","Romiplostim has demonstrated its efficacy and good tolerance in multiple indications. If the efficacy of Romiplostim is confirmed in this population, thrombocytopenic patients will be able to undergo cardiac surgery, which is generally life-saving, without prior thrombocytopenia.\n\nPatients included in the study will be hospitalized within 15 days of the first administration of the study treatment and will be closely monitored clinically and biologically for at least 10 days after surgery. The occurrence of an adverse event can therefore be quickly detected and managed.\n\nCollectively, \"Patient Blood Management\" strategies are mainly focused on the management of preoperative anemia. If positive, this study will enrich the therapeutic arsenal available for optimizing patients in preparation for major surgery. As no major collective complications are expected, the collective benefit\u002Frisk ratio also appears favorable.",[62,28],"Chirurgical Intervention",[64,65,66,67],"Thrombocytopenia","Cardiac Surgery","Growth Factor","Patient Blood Management","2026-03-31",{"date":70,"type":39},"2026-04-06",{"date":72,"type":21},"2026-09-01",{"date":74,"type":21},"2028-12-01",{"name":76,"class":46},"Nantes University Hospital",8,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100577961","clinical-efficacy-of-platelet-transfusion-100577961","NCT06805097","Clinical Efficacy of Platelet Transfusion","ECLAT","Inclusion Criteria:\n\n* Patients with haematological malignancies or bone marrow aplasia with severe thrombocytopenia due to bone marrow failure related to the disease or treatments received\n* Severe thrombocytopenia requiring transfusion\n* Patient able to self-assess bleeding events\n* Non-opposition of the subject to participate in the study\n* Registered with the French social security system or benefiting from such a system.\n\nExclusion Criteria:\n\n* Acute promyelocytic leukaemia\n* Curative dosage of anticoagulants\n* Treatment with antiplatelet agents\n* Patient with proven thrombocytopenia of immunological origin, or disseminated intravascular coagulation\n* Patients with a clinically significant haemorrhagic event (WHO grade 2) in the 48 hours prior to transfusion\n* Indication for deplasmatised, cryopreserved and reduced-volume PCs\n* Patient refusing transfusion of labile blood products\n* Pregnant women or breast-feeding mothers\n* Adults subject to a legal protection measure or unable to express their consent\n* Persons deprived of their liberty by a judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a health or social care institution for purposes other than research\n* Subject in the exclusion period of another study",{"count":86,"type":21},343,"OBSERVATIONAL","The aim of this study is to analyze the effect of the storage time of platelet concentrates on the occurrence of bleeding events during prophylactic platelet transfusions in patients with hematological malignancies.",[28,90],"Haematological Malignancies",[92,93,94],"platelet concentrate","transfusion","haemorrhage","2025-07-04",{"date":97,"type":39},"2025-07-09",{"date":99,"type":39},"2025-06-17",{"date":101,"type":21},"2028-07",{"name":103,"class":46},"Centre Hospitalier Universitaire de Besancon",1]